Difference between revisions of "User:Bdholaria"
(Created page with "thumb|Bhagirathbhai Dholaria, MDDr. Dholaria is an assistant professor in the Department of Hematology-Oncology at Vanderbilt University Medical Center,...") |
Warner-admin (talk | contribs) |
||
| Line 1: | Line 1: | ||
[[File:Bdholaria.jpg|thumb|Bhagirathbhai Dholaria, MD]]Dr. Dholaria is an assistant professor in the Department of Hematology-Oncology at Vanderbilt University Medical Center, Nashville, TN. His areas of specialization and primary research focus are lymphoid and plasma cell malignancies, adoptive cellular therapeutics, and stem cell transplantation. He has conducted studies investigating the outcomes of non-Hodgkin lymphoma patients undergoing chimeric antigen receptor T-cell (CAR-T) therapies. He is involved in translational research investigating the biomarkers of CAR T-cell therapy-associated toxicities. He has also conducted several observational studies utilizing cancer registries to study transplant outcomes of acute leukemia patients and presented his findings in national meetings. His team’s work on stem cell transplantation has been published in multiple manuscripts. His current research efforts are focused on testing novel agents to mitigate cytokine release syndrome and neurotoxicity associated with CAR T-cell therapy. | [[File:Bdholaria.jpg|thumb|Bhagirathbhai Dholaria, MD]]Dr. Dholaria is an assistant professor in the Department of Hematology-Oncology at Vanderbilt University Medical Center, Nashville, TN. His areas of specialization and primary research focus are lymphoid and plasma cell malignancies, adoptive cellular therapeutics, and stem cell transplantation. He has conducted studies investigating the outcomes of non-Hodgkin lymphoma patients undergoing chimeric antigen receptor T-cell (CAR-T) therapies. He is involved in translational research investigating the biomarkers of CAR T-cell therapy-associated toxicities. He has also conducted several observational studies utilizing cancer registries to study transplant outcomes of acute leukemia patients and presented his findings in national meetings. His team’s work on stem cell transplantation has been published in multiple manuscripts. His current research efforts are focused on testing novel agents to mitigate cytokine release syndrome and neurotoxicity associated with CAR T-cell therapy. | ||
| + | |||
| + | He is the HemOnc.org Section Editor of [[:Category:T-cell neoplasms|T-cell and NK-cell Neoplasms]]. | ||
Latest revision as of 00:29, 29 August 2023
Dr. Dholaria is an assistant professor in the Department of Hematology-Oncology at Vanderbilt University Medical Center, Nashville, TN. His areas of specialization and primary research focus are lymphoid and plasma cell malignancies, adoptive cellular therapeutics, and stem cell transplantation. He has conducted studies investigating the outcomes of non-Hodgkin lymphoma patients undergoing chimeric antigen receptor T-cell (CAR-T) therapies. He is involved in translational research investigating the biomarkers of CAR T-cell therapy-associated toxicities. He has also conducted several observational studies utilizing cancer registries to study transplant outcomes of acute leukemia patients and presented his findings in national meetings. His team’s work on stem cell transplantation has been published in multiple manuscripts. His current research efforts are focused on testing novel agents to mitigate cytokine release syndrome and neurotoxicity associated with CAR T-cell therapy.
He is the HemOnc.org Section Editor of T-cell and NK-cell Neoplasms.